BackGovt allows Serum Institute to enrol 7-11 year olds in Covid-19 vaccine trial
Two Indian vaccine makers — Bharat Biotech (Covaxin) and Zydus Cadila (ZyCoV-D) — have already started trials on children.
PremiumIndia's drug regulator on Tuesday allowed vaccine manufacturer Serum Institute to enroll children between seven and 11 years of age for its COVID-19 vaccine trial, according to Reuters.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of AstraZeneca's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
